Clinical Report: Investigating the Learning Curve in Pharmacist Training

Overview

This study evaluates the learning curve of pharmacy trainees in reviewing high-risk narcotic and psychotropic prescriptions. Results indicate that proficiency is achieved after approximately 600–700 reviewed prescriptions.

Background

Pharmacists play a crucial role in ensuring the safe use of narcotic and psychotropic medications, which are associated with significant risks of addiction and misuse. Inadequate training and workforce shortages in primary healthcare settings necessitate effective training programs.

Data Highlights

Key Findings

• Group-level proficiency plateaued at step 7 after reviewing 600–700 prescriptions.
• Individual learning curves flattened between steps 4 and 9.
• Prior front-line pharmacy experience negatively correlated with the number of steps to reach proficiency (r = −0.521, p = 0.018).
• Terminology proficiency plateaued at step 6.
• Monitoring learning curves can guide individualized instruction.

Clinical Implications

Continuous monitoring of trainees' progress can facilitate targeted educational interventions.

Conclusion

Learning curve analysis provides a framework for assessing skill acquisition in prescription review.

Related Resources & Content

1. CDC Clinical Practice Guideline for Prescribing Opioids for Pain, 2022 -- PMC
2. FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine | FDA
3. American Journal of Epidemiology — Pharmacoepidemiological Interventions: Strategies for Enhancing Prescription Practices
4. American Journal of Epidemiology — Evaluating Various Modeling Approaches for Low-Dose Medication Associations and Health Outcomes: A Simulation Analysis Focused on Postpartum Opioid Use
5. conexiant — Side Effects: Nobody Trained for This
6. Pain Medicine — Understanding the first prescription: clinical and demographic drivers of strong opioid use in primary care
7. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 - PMC
8. FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine | FDA
9. ASHP Guidelines on Preventing Diversion of Controlled Substances | American Journal of Health-System Pharmacy | Oxford Academic